CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a ...

Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long struggling to ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Skye Bioscience (NASDAQ: SKYE) is a micro-cap pharmaceutical company that is striving to become the next big thing in the weight loss drug space. The massive success of glucagon-like peptide-1 (GLP-1) ...

Eli Lilly (LLY) is considering testing its blockbuster weight-loss drugs in individuals who are not yet overweight but are at risk of weight gain, according to an exclusive Financial Times report.

the active ingredient in its weight-loss drug, Zepbound. The lawsuits aim to stop the sale of unapproved tirzepatide products and seek monetary damages. Eli Lilly And Co LLY has reportedly sued ...

Eli Lilly (LLY) stock is soaring Thursday after the ... driven by demand for its weight-loss drugs, Mounjaro and Zepbound, as well as its breast cancer drug Verzenio. Its earnings per share ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

(Reuters) - Americans are still eagerly seeking prescriptions for Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO)'s weight-loss and diabetes drugs but cannot always fill them because of supply ...

The massive success of glucagon-like peptide-1 (GLP-1) agonist drugs sold by Eli Lilly LLY and Novo Nordisk has ... with GLP-1s to possibly enhance weight loss or simply offer an alternative ...